文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

高剂量早期活动对糖尿病患者结局的影响:TEAM试验的二次分析

Impact of High-Dose Early Mobilization on Outcomes for Patients with Diabetes: A Secondary Analysis of the TEAM Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论TEAM试验二次分析显示,糖尿病患者接受高剂量早期活动策略后180天死亡风险增加(校正OR 3.47,95%CI 1.67-7.61),而存活出院天数未显著减少。

该研究为TEAM试验的二次分析,纳入全部741例患者,其中159例(21.4%)合并糖尿病,旨在评估糖尿病是否修饰早期活动剂量与临床结局的关系。主要终点为180天存活且出院天数,次要终点包括180天死亡率和180天长期功能结局。糖尿病患者180天存活出院天数更少(124 vs 147,P=0.013),180天死亡率更高(30% vs 18%,P=0.044)。在糖尿病患者中,高剂量早期活动增加180天死亡风险(校正OR 3.47,95%CI 1.67-7.61;交互作用P=0.001),而存活出院天数在糖尿病与非糖尿病患者中分别为73.0和146.5(交互作用P=0.108)。

要点

  • 在糖尿病患者中,高剂量早期活动增加180天死亡风险(校正OR 3.47,95%CI 1.67-7.61;交互作用P=0.001)。
  • 糖尿病患者180天存活出院天数少于非糖尿病患者(124 vs 147,P=0.013),180天死亡率更高(30% vs 18%,P=0.044)。
  • 接受高剂量早期活动的糖尿病患者180天存活出院天数为73.0,非糖尿病患者为146.5(交互作用P=0.108)。
  • 该分析纳入TEAM试验全部741例患者,其中159例(21.4%)合并糖尿病。

适用人群与场景

  • TEAM试验全部741例ICU患者,其中159例(21.4%)合并糖尿病。

研究设计与关键结果

  • 研究类型:TEAM试验的二次分析;样本量:741例患者,其中159例(21.4%)合并糖尿病。
  • 主要终点:糖尿病患者180天存活出院天数少于非糖尿病患者(124 [0-153] vs 147 [82-164];P=0.013)。
  • 次要终点:糖尿病患者180天死亡率高于非糖尿病患者(30% vs 18%;P=0.044)。
  • 在糖尿病患者中,高剂量早期活动增加180天死亡风险(校正OR 3.47;95%CI 1.67-7.61;交互作用P=0.001)。
  • 接受高剂量早期活动者,糖尿病患者180天存活出院天数为73.0(0.0-144.5),非糖尿病患者为146.5(95.8-163.0);交互作用P=0.108。

证据类型、等级与局限

  • 证据类型:RCT(TEAM试验)的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在糖尿病患者中,高剂量早期活动策略未显著减少180天存活出院天数,但增加了180天死亡率。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Patients with diabetes represent almost 20% of all ICU admissions and might respond differently to high-dose early active mobilization. Objectives: To assess whether diabetes modified the relationship between the dose of early mobilization on clinical outcomes in the TEAM trial. Methods: All TEAM trial patients were included. The primary outcome was days alive and out of the hospital at Day 180. Secondary outcomes included 180-day mortality and long-term functional outcomes at Day 180. Logistic and median regression models were used to explore the effect of high-dose early mobilization on outcomes by diabetes status. Measurements and Main Results: All 741 patients from the original trial were included. Of these, 159 patients (21.4%) had diabetes. Patients with diabetes had fewer days alive and out of the hospital at Day 180 (124 [0-153] vs. 147 [82-164]; P = 0.013) and higher 180-day mortality (30% vs. 18%; P = 0.044). In patients receiving high-dose early mobilization, the number of days alive and out of the hospital at Day 180 was 73.0 (0.0-144.5) in patients with diabetes and 146.5 (95.8-163.0) in patients without diabetes (P value for interaction = 0.108). However, in patients with diabetes, high-dose early mobilization increased the odds of mortality at 180 days (adjusted odds ratio, 3.47; 95% confidence interval, 1.67-7.61; P value for interaction = 0.001). Conclusions: In this secondary analysis of the TEAM trial, in patients with diabetes, a high-dose early mobilization strategy did not significantly decrease the number of days alive and out of the hospital at Day 180, but it increased 180-day mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Serpa Neto A, Bailey M, Seller D, et al. Impact of High-Dose Early Mobilization on Outcomes for Patients with Diabetes: A Secondary Analysis of the TEAM Trial. Am J Respir Crit Care Med. 2024. PMID: 38763167. doi:10.1164/rccm.202312-2289OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。